News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) Announces Presentation Of Data For CUDC-907, CUDC-427 And Debio 0932 At American Association for Cancer Research Annual Meeting


3/31/2014 9:34:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5th to 9th in San Diego, CA. Curis researchers will present data for two of its proprietary targeted cancer drug candidates, CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, an antagonist of IAP proteins.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES